EMA recommends approval of a locally targeted treatment for ulcerative colitis
Entyvio (vedolizumab) offers a treatment option for patients who do not respond to standard therapies
Ulcerative colitis and Crohn’s disease are the two most common types of inflammatory bowel disease. They are chronic auto-immune diseases that cause considerable ill health and mortality in patients, and affect more than two million people across the European Union. Moreover, both ulcerative colitis and Crohn’s disease patients have an increased risk of developing colon cancer.
Current therapies for ulcerative colitis and Crohn’s disease have a broad mechanism of action, potentially leading to serious side effects including systemic immunosuppression, serious infection and certain types of cancer. Furthermore, some ulcerative colitis and Crohn’s disease patients have an inadequate response to, or do not tolerate standard therapies. These patients have no other medical therapeutic option available and often require surgical treatment.
Entyvio is a monoclonal antibody whose mechanism of action is based upon its specific binding of theα4β7 integrin, a key mediator of gastrointestinal inflammation. It was developed to address the unmet medical need recognised in moderately to severely active ulcerative colitis and Crohn’s disease patients. This novel mechanism of action allows for a more selective, intestinal-targeted anti-inflammatory activity and it may offer a significant additional treatment option for the management of ulcerative colitis and Crohn’s disease patients who have failed standard available therapies.
The CHMP opinion on Entyvio will now be sent to the European Commission for adoption of a decision on an EU-wide marketing-authorisation.
Most read news
Other news from the department politics & laws
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.